139 related articles for article (PubMed ID: 7493290)
1. Approaches to the development of novel inhibitors of hepatitis C virus replication.
Clarke BE
J Viral Hepat; 1995; 2(1):1-8. PubMed ID: 7493290
[TBL] [Abstract][Full Text] [Related]
2. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
3. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
4. Current and future concepts in hepatitis C therapy.
Pawlotsky JM
Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline.
Huang M; Deshpande M
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):375-88. PubMed ID: 15482203
[TBL] [Abstract][Full Text] [Related]
6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
7. Advances in hepatitis C: what is coming in the next 5 years?
Locarnini SA; Bartholomeusz A
J Gastroenterol Hepatol; 2002 Apr; 17(4):442-7. PubMed ID: 11982725
[TBL] [Abstract][Full Text] [Related]
8. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
[No Abstract] [Full Text] [Related]
9. Existing and future therapeutic options for hepatitis C virus infection.
Bretner M
Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
[TBL] [Abstract][Full Text] [Related]
10. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
Zhao Q; Xia N
Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
[No Abstract] [Full Text] [Related]
11. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
[TBL] [Abstract][Full Text] [Related]
12. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
13. New therapies on the horizon for hepatitis C: are we close?
De Francesco R; Rice CM
Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies.
Randall G; Rice CM
Curr Opin Infect Dis; 2001 Dec; 14(6):743-7. PubMed ID: 11964894
[TBL] [Abstract][Full Text] [Related]
15. Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.
Boettler T; Moradpour D; Thimme R; Zoulim F
J Hepatol; 2014 Sep; 61(3):696-705. PubMed ID: 24845610
[TBL] [Abstract][Full Text] [Related]
16. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
17. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
Watashi K; Metselaar HJ; van der Laan LJ
Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
[No Abstract] [Full Text] [Related]
18. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
19. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilin inhibitors.
Gallay PA
Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
